What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.”In the company’s words, NCT06590246 on ClinicalTrials.gov
- Main trialPhase 1/2
- “This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.”In the company’s words, NCT06590246 on ClinicalTrials.gov
Other drugs for Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up2
- 30 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Apr 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 30 Apr 2030 | A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) | |
| Phase 1Recruiting | 30 Apr 2027 | An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026